Prostate cancer biomarker annexin A3 detected in urines obtained following digital rectal examination presents antigenic variability
Annexin A3 (ANXA3) is a potential marker for prostate cancer (PCa). We aimed to develop robust immunoassays suitable for quantifying ANXA3 in urine samples obtained following digital rectal examination (DRE) in order to facilitate the diagnostic performance evaluation of this marker. Anti-ANXA3 mono...
Gespeichert in:
| Veröffentlicht in: | Clinical biochemistry 2014-07, Vol.47 (10-11), p.901-908 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 908 |
|---|---|
| container_issue | 10-11 |
| container_start_page | 901 |
| container_title | Clinical biochemistry |
| container_volume | 47 |
| creator | Hamelin-Peyron, Céline Vlaeminck-Guillem, Virginie Haïdous, Hader Schwall, Gerhard P. Poznanović, Slobodan Gorius-Gallet, Emmanuelle Michel, Sandrine Larue, Audrey Guillotte, Michèle Ruffion, Alain Choquet-Kastylevsky, Geneviève Ataman-Önal, Yasemin |
| description | Annexin A3 (ANXA3) is a potential marker for prostate cancer (PCa). We aimed to develop robust immunoassays suitable for quantifying ANXA3 in urine samples obtained following digital rectal examination (DRE) in order to facilitate the diagnostic performance evaluation of this marker.
Anti-ANXA3 monoclonal antibodies were generated and their epitopes mapped. Two different ANXA3 assay prototypes were established on the VIDAS® automated immunoanalyser and analytical validation was carried out using post-DRE urine samples obtained from patients with PCa (n=23) or benign prostate hyperplasia (n=31).
The assays had the same capture antibody (TGC44) but different detection antibodies (13A12 or 5C5), recognizing novel distinct epitopes. Both had a lower limit of quantification |
| doi_str_mv | 10.1016/j.clinbiochem.2014.05.063 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02641221v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0009912014003300</els_id><sourcerecordid>1544737827</sourcerecordid><originalsourceid>FETCH-LOGICAL-c514t-8039022813adf5b8914a942fc96d9eafd53af205d3cc0da42b88dc57aa018e593</originalsourceid><addsrcrecordid>eNqNkcuOEzEQRVsIxISBX0BmB4s0fvXDyygCBikSLGBtVdvVmQodd7CdMLPnw3GUYcSSVVVZp27J91bVG8FrwUX7fle7icJAs7vFfS250DVvat6qJ9VC9J1aSqPU02rBOTdLIyS_ql6ktCuj1H37vLqS2jS6NXJR_f4a55QhI3MQHEZWVPcQf5QOQsA7CmylmMeMLqNnZTxGCpjYPGQojWfjPE3zLwpb5mlLGSYWC1sK3sGeAmSaAztETBhyKqKZthjIsRNEgoEmyvcvq2cjTAlfPdTr6vvHD9_WN8vNl0-f16vN0jVC52XPleFS9kKBH5uhN0KD0XJ0pvUGYfSNglHyxivnuActh773rukAuOixMeq6enfRvYXJHiKVj97bGcjerDb2_MZlq4WU4iQK-_bCHuL884gp2z0lh9MEAedjsqLRulNdL7uCmgvqipcp4vioLbg9B2Z39p_A7DkwyxtbAiu7rx_OHIc9-sfNvwkVYH0BsBhzIow2OcISlaezz9bP9B9n_gDela-D</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1544737827</pqid></control><display><type>article</type><title>Prostate cancer biomarker annexin A3 detected in urines obtained following digital rectal examination presents antigenic variability</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hamelin-Peyron, Céline ; Vlaeminck-Guillem, Virginie ; Haïdous, Hader ; Schwall, Gerhard P. ; Poznanović, Slobodan ; Gorius-Gallet, Emmanuelle ; Michel, Sandrine ; Larue, Audrey ; Guillotte, Michèle ; Ruffion, Alain ; Choquet-Kastylevsky, Geneviève ; Ataman-Önal, Yasemin</creator><creatorcontrib>Hamelin-Peyron, Céline ; Vlaeminck-Guillem, Virginie ; Haïdous, Hader ; Schwall, Gerhard P. ; Poznanović, Slobodan ; Gorius-Gallet, Emmanuelle ; Michel, Sandrine ; Larue, Audrey ; Guillotte, Michèle ; Ruffion, Alain ; Choquet-Kastylevsky, Geneviève ; Ataman-Önal, Yasemin</creatorcontrib><description>Annexin A3 (ANXA3) is a potential marker for prostate cancer (PCa). We aimed to develop robust immunoassays suitable for quantifying ANXA3 in urine samples obtained following digital rectal examination (DRE) in order to facilitate the diagnostic performance evaluation of this marker.
Anti-ANXA3 monoclonal antibodies were generated and their epitopes mapped. Two different ANXA3 assay prototypes were established on the VIDAS® automated immunoanalyser and analytical validation was carried out using post-DRE urine samples obtained from patients with PCa (n=23) or benign prostate hyperplasia (n=31).
The assays had the same capture antibody (TGC44) but different detection antibodies (13A12 or 5C5), recognizing novel distinct epitopes. Both had a lower limit of quantification <1ng/mL and were highly specific for ANXA3, not cross-reacting with other annexins. Interassay imprecision was ≤11% and ≤15% for 13A12 and 5C5 assays, respectively. Surprisingly, a total lack of correlation was observed between ANXA3 levels measured by these two assays in post-DRE urines, indicating detection of distinct antigenic variants. Two freeze–thaw cycles did not affect analyte stability in either assay, whereas a lack of stability of antigenic variants was observed when samples were stored at −80°C for 1month.
Two different antigenic variants of ANXA3 are present in post-DRE urines and their clinical significance for diagnosis of prostate cancer should be further investigated. These variants are not stable over time in samples preserved at −80°C. Until this issue is resolved, ANXA3 should only be measured in freshly collected samples.
[Display omitted]
•Anti-ANXA3 monoclonal antibodies were generated and their epitopes mapped.•Two different immunoassays, sensitive, precise and specific for ANXA3, were developed.•Two different antigenic variants of ANXA3 are present in post-DRE urines.•These variants are not stable in samples stored at −80°C for 1month.</description><identifier>ISSN: 0009-9120</identifier><identifier>EISSN: 1873-2933</identifier><identifier>DOI: 10.1016/j.clinbiochem.2014.05.063</identifier><identifier>PMID: 24954692</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Annexin A3 - urine ; Antibodies, Monoclonal, Murine-Derived - chemistry ; Antibodies, Neoplasm - chemistry ; Antigenic variant ; ANXA3 ; Biomarkers, Tumor - urine ; Cryopreservation ; Digital Rectal Examination ; Enzyme-Linked Immunosorbent Assay ; Epitopes - urine ; Humans ; Life Sciences ; Male ; Mice ; Mice, Inbred BALB C ; Neoplasm Proteins - urine ; Prostate cancer ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - urine ; Protein Stability ; Sandwich immunoassay ; Urinary biomarker</subject><ispartof>Clinical biochemistry, 2014-07, Vol.47 (10-11), p.901-908</ispartof><rights>2014 The Canadian Society of Clinical Chemists</rights><rights>Copyright © 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c514t-8039022813adf5b8914a942fc96d9eafd53af205d3cc0da42b88dc57aa018e593</citedby><cites>FETCH-LOGICAL-c514t-8039022813adf5b8914a942fc96d9eafd53af205d3cc0da42b88dc57aa018e593</cites><orcidid>0000-0002-3426-6734 ; 0000-0003-0512-3459</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0009912014003300$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24954692$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.inrae.fr/hal-02641221$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Hamelin-Peyron, Céline</creatorcontrib><creatorcontrib>Vlaeminck-Guillem, Virginie</creatorcontrib><creatorcontrib>Haïdous, Hader</creatorcontrib><creatorcontrib>Schwall, Gerhard P.</creatorcontrib><creatorcontrib>Poznanović, Slobodan</creatorcontrib><creatorcontrib>Gorius-Gallet, Emmanuelle</creatorcontrib><creatorcontrib>Michel, Sandrine</creatorcontrib><creatorcontrib>Larue, Audrey</creatorcontrib><creatorcontrib>Guillotte, Michèle</creatorcontrib><creatorcontrib>Ruffion, Alain</creatorcontrib><creatorcontrib>Choquet-Kastylevsky, Geneviève</creatorcontrib><creatorcontrib>Ataman-Önal, Yasemin</creatorcontrib><title>Prostate cancer biomarker annexin A3 detected in urines obtained following digital rectal examination presents antigenic variability</title><title>Clinical biochemistry</title><addtitle>Clin Biochem</addtitle><description>Annexin A3 (ANXA3) is a potential marker for prostate cancer (PCa). We aimed to develop robust immunoassays suitable for quantifying ANXA3 in urine samples obtained following digital rectal examination (DRE) in order to facilitate the diagnostic performance evaluation of this marker.
Anti-ANXA3 monoclonal antibodies were generated and their epitopes mapped. Two different ANXA3 assay prototypes were established on the VIDAS® automated immunoanalyser and analytical validation was carried out using post-DRE urine samples obtained from patients with PCa (n=23) or benign prostate hyperplasia (n=31).
The assays had the same capture antibody (TGC44) but different detection antibodies (13A12 or 5C5), recognizing novel distinct epitopes. Both had a lower limit of quantification <1ng/mL and were highly specific for ANXA3, not cross-reacting with other annexins. Interassay imprecision was ≤11% and ≤15% for 13A12 and 5C5 assays, respectively. Surprisingly, a total lack of correlation was observed between ANXA3 levels measured by these two assays in post-DRE urines, indicating detection of distinct antigenic variants. Two freeze–thaw cycles did not affect analyte stability in either assay, whereas a lack of stability of antigenic variants was observed when samples were stored at −80°C for 1month.
Two different antigenic variants of ANXA3 are present in post-DRE urines and their clinical significance for diagnosis of prostate cancer should be further investigated. These variants are not stable over time in samples preserved at −80°C. Until this issue is resolved, ANXA3 should only be measured in freshly collected samples.
[Display omitted]
•Anti-ANXA3 monoclonal antibodies were generated and their epitopes mapped.•Two different immunoassays, sensitive, precise and specific for ANXA3, were developed.•Two different antigenic variants of ANXA3 are present in post-DRE urines.•These variants are not stable in samples stored at −80°C for 1month.</description><subject>Animals</subject><subject>Annexin A3 - urine</subject><subject>Antibodies, Monoclonal, Murine-Derived - chemistry</subject><subject>Antibodies, Neoplasm - chemistry</subject><subject>Antigenic variant</subject><subject>ANXA3</subject><subject>Biomarkers, Tumor - urine</subject><subject>Cryopreservation</subject><subject>Digital Rectal Examination</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Epitopes - urine</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Neoplasm Proteins - urine</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - urine</subject><subject>Protein Stability</subject><subject>Sandwich immunoassay</subject><subject>Urinary biomarker</subject><issn>0009-9120</issn><issn>1873-2933</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkcuOEzEQRVsIxISBX0BmB4s0fvXDyygCBikSLGBtVdvVmQodd7CdMLPnw3GUYcSSVVVZp27J91bVG8FrwUX7fle7icJAs7vFfS250DVvat6qJ9VC9J1aSqPU02rBOTdLIyS_ql6ktCuj1H37vLqS2jS6NXJR_f4a55QhI3MQHEZWVPcQf5QOQsA7CmylmMeMLqNnZTxGCpjYPGQojWfjPE3zLwpb5mlLGSYWC1sK3sGeAmSaAztETBhyKqKZthjIsRNEgoEmyvcvq2cjTAlfPdTr6vvHD9_WN8vNl0-f16vN0jVC52XPleFS9kKBH5uhN0KD0XJ0pvUGYfSNglHyxivnuActh773rukAuOixMeq6enfRvYXJHiKVj97bGcjerDb2_MZlq4WU4iQK-_bCHuL884gp2z0lh9MEAedjsqLRulNdL7uCmgvqipcp4vioLbg9B2Z39p_A7DkwyxtbAiu7rx_OHIc9-sfNvwkVYH0BsBhzIow2OcISlaezz9bP9B9n_gDela-D</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Hamelin-Peyron, Céline</creator><creator>Vlaeminck-Guillem, Virginie</creator><creator>Haïdous, Hader</creator><creator>Schwall, Gerhard P.</creator><creator>Poznanović, Slobodan</creator><creator>Gorius-Gallet, Emmanuelle</creator><creator>Michel, Sandrine</creator><creator>Larue, Audrey</creator><creator>Guillotte, Michèle</creator><creator>Ruffion, Alain</creator><creator>Choquet-Kastylevsky, Geneviève</creator><creator>Ataman-Önal, Yasemin</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-3426-6734</orcidid><orcidid>https://orcid.org/0000-0003-0512-3459</orcidid></search><sort><creationdate>20140701</creationdate><title>Prostate cancer biomarker annexin A3 detected in urines obtained following digital rectal examination presents antigenic variability</title><author>Hamelin-Peyron, Céline ; Vlaeminck-Guillem, Virginie ; Haïdous, Hader ; Schwall, Gerhard P. ; Poznanović, Slobodan ; Gorius-Gallet, Emmanuelle ; Michel, Sandrine ; Larue, Audrey ; Guillotte, Michèle ; Ruffion, Alain ; Choquet-Kastylevsky, Geneviève ; Ataman-Önal, Yasemin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c514t-8039022813adf5b8914a942fc96d9eafd53af205d3cc0da42b88dc57aa018e593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Annexin A3 - urine</topic><topic>Antibodies, Monoclonal, Murine-Derived - chemistry</topic><topic>Antibodies, Neoplasm - chemistry</topic><topic>Antigenic variant</topic><topic>ANXA3</topic><topic>Biomarkers, Tumor - urine</topic><topic>Cryopreservation</topic><topic>Digital Rectal Examination</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Epitopes - urine</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Neoplasm Proteins - urine</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - urine</topic><topic>Protein Stability</topic><topic>Sandwich immunoassay</topic><topic>Urinary biomarker</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hamelin-Peyron, Céline</creatorcontrib><creatorcontrib>Vlaeminck-Guillem, Virginie</creatorcontrib><creatorcontrib>Haïdous, Hader</creatorcontrib><creatorcontrib>Schwall, Gerhard P.</creatorcontrib><creatorcontrib>Poznanović, Slobodan</creatorcontrib><creatorcontrib>Gorius-Gallet, Emmanuelle</creatorcontrib><creatorcontrib>Michel, Sandrine</creatorcontrib><creatorcontrib>Larue, Audrey</creatorcontrib><creatorcontrib>Guillotte, Michèle</creatorcontrib><creatorcontrib>Ruffion, Alain</creatorcontrib><creatorcontrib>Choquet-Kastylevsky, Geneviève</creatorcontrib><creatorcontrib>Ataman-Önal, Yasemin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Clinical biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamelin-Peyron, Céline</au><au>Vlaeminck-Guillem, Virginie</au><au>Haïdous, Hader</au><au>Schwall, Gerhard P.</au><au>Poznanović, Slobodan</au><au>Gorius-Gallet, Emmanuelle</au><au>Michel, Sandrine</au><au>Larue, Audrey</au><au>Guillotte, Michèle</au><au>Ruffion, Alain</au><au>Choquet-Kastylevsky, Geneviève</au><au>Ataman-Önal, Yasemin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prostate cancer biomarker annexin A3 detected in urines obtained following digital rectal examination presents antigenic variability</atitle><jtitle>Clinical biochemistry</jtitle><addtitle>Clin Biochem</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>47</volume><issue>10-11</issue><spage>901</spage><epage>908</epage><pages>901-908</pages><issn>0009-9120</issn><eissn>1873-2933</eissn><abstract>Annexin A3 (ANXA3) is a potential marker for prostate cancer (PCa). We aimed to develop robust immunoassays suitable for quantifying ANXA3 in urine samples obtained following digital rectal examination (DRE) in order to facilitate the diagnostic performance evaluation of this marker.
Anti-ANXA3 monoclonal antibodies were generated and their epitopes mapped. Two different ANXA3 assay prototypes were established on the VIDAS® automated immunoanalyser and analytical validation was carried out using post-DRE urine samples obtained from patients with PCa (n=23) or benign prostate hyperplasia (n=31).
The assays had the same capture antibody (TGC44) but different detection antibodies (13A12 or 5C5), recognizing novel distinct epitopes. Both had a lower limit of quantification <1ng/mL and were highly specific for ANXA3, not cross-reacting with other annexins. Interassay imprecision was ≤11% and ≤15% for 13A12 and 5C5 assays, respectively. Surprisingly, a total lack of correlation was observed between ANXA3 levels measured by these two assays in post-DRE urines, indicating detection of distinct antigenic variants. Two freeze–thaw cycles did not affect analyte stability in either assay, whereas a lack of stability of antigenic variants was observed when samples were stored at −80°C for 1month.
Two different antigenic variants of ANXA3 are present in post-DRE urines and their clinical significance for diagnosis of prostate cancer should be further investigated. These variants are not stable over time in samples preserved at −80°C. Until this issue is resolved, ANXA3 should only be measured in freshly collected samples.
[Display omitted]
•Anti-ANXA3 monoclonal antibodies were generated and their epitopes mapped.•Two different immunoassays, sensitive, precise and specific for ANXA3, were developed.•Two different antigenic variants of ANXA3 are present in post-DRE urines.•These variants are not stable in samples stored at −80°C for 1month.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24954692</pmid><doi>10.1016/j.clinbiochem.2014.05.063</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3426-6734</orcidid><orcidid>https://orcid.org/0000-0003-0512-3459</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9120 |
| ispartof | Clinical biochemistry, 2014-07, Vol.47 (10-11), p.901-908 |
| issn | 0009-9120 1873-2933 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02641221v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Annexin A3 - urine Antibodies, Monoclonal, Murine-Derived - chemistry Antibodies, Neoplasm - chemistry Antigenic variant ANXA3 Biomarkers, Tumor - urine Cryopreservation Digital Rectal Examination Enzyme-Linked Immunosorbent Assay Epitopes - urine Humans Life Sciences Male Mice Mice, Inbred BALB C Neoplasm Proteins - urine Prostate cancer Prostatic Neoplasms - diagnosis Prostatic Neoplasms - urine Protein Stability Sandwich immunoassay Urinary biomarker |
| title | Prostate cancer biomarker annexin A3 detected in urines obtained following digital rectal examination presents antigenic variability |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T21%3A14%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prostate%20cancer%20biomarker%20annexin%20A3%20detected%20in%20urines%20obtained%20following%20digital%20rectal%20examination%20presents%20antigenic%20variability&rft.jtitle=Clinical%20biochemistry&rft.au=Hamelin-Peyron,%20C%C3%A9line&rft.date=2014-07-01&rft.volume=47&rft.issue=10-11&rft.spage=901&rft.epage=908&rft.pages=901-908&rft.issn=0009-9120&rft.eissn=1873-2933&rft_id=info:doi/10.1016/j.clinbiochem.2014.05.063&rft_dat=%3Cproquest_hal_p%3E1544737827%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1544737827&rft_id=info:pmid/24954692&rft_els_id=S0009912014003300&rfr_iscdi=true |